Identification of arylamine N -acetyltransferase inhibitors as an approach towards
novel anti-tuberculars
1.Department of Pharmacology,
University of Oxford, Oxford OX1 3QT, United Kingdom;Chemistry Research Laboratory,
Department of Organic Chemistry, University of Oxford, Oxford OX1
3QL, United Kingdom;Current address: Structure-Based
Drug Design Team, Sections of Structural Biology and Cancer Therapeutics,
Institute of Cancer Research, Chester Beatty Laboratories, London
SW3 6JB, United Kingdom; 2.Department of Pharmacology,
University of Oxford, Oxford OX1 3QT, United Kingdom;Current address: Institute
of Structural and Molecular Biology, Department of Biological Science,
Birkbeck, University of London, London WC1E 7HX, United Kingdom; 3.Department of Pharmacology,
University of Oxford, Oxford OX1 3QT, United Kingdom;Chemistry Research Laboratory,
Department of Organic Chemistry, University of Oxford, Oxford OX1
3QL, United Kingdom; 4.Department of Pharmacology,
University of Oxford, Oxford OX1 3QT, United Kingdom; 5.Chemistry Research Laboratory,
Department of Organic Chemistry, University of Oxford, Oxford OX1
3QL, United Kingdom; 6.School of Biosciences,
University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom; 7.Tuberculosis Immunology
Group, Department of Respiratory Medicine, National Heart and Lung
Institute, Wright Fleming Institute of Infection and Immunity, Imperial
College London, Norfolk Place, London W2 1PG, United Kingdom;
Show less